Skip to main content
Mydecine Innovations Group Inc. logo

Mydecine Innovations Group Inc. — Investor Relations & Filings

Ticker · MYCO ISIN · CA62849F4087 LEI · 254900C6LWGCB35YSK30 CSE Professional, scientific and technical activities
Open in API
Filings indexed 413 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country CA Canada
Listing CSE MYCO

About Mydecine Innovations Group Inc.

https://www.mydecine.com/

Mydecine Innovations Group Inc. is a biotechnology and life sciences company focused on the research, development, and commercialization of innovative first- and second-generation novel therapeutics. The company is dedicated to addressing mental health conditions and addiction, particularly target indications with high mortality rates that have historically lacked innovation. Mydecine utilizes nature-sourced compounds, such as psilocybin, in its pipeline development. Key therapeutic areas include Post-Traumatic Stress Disorder (PTSD) and nicotine addiction. The company's pipeline includes specific drug candidates such as MYCO-005, MYCO-006, and MYCO-007.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing the signing of an advisory agreement to provide market making and liquidity services. It is not an annual or interim financial report, earnings release, management change, financing round, share issuance, or any other narrowly defined category. Therefore, it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-23 English
News release - English.pdf
Regulatory Filings Classification · 80% confidence The document is a short press release announcing the signing of an advisory agreement for market making services. It does not report financial results, management changes, fundraising, dividends, share issuances, or other specific categories. It is a general corporate announcement that falls into the fallback regulatory announcement category.
2026-04-23 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a clarifying news release issued by Noveris Health Sciences Inc. regarding its LIFE Offering and related disclosures. It discusses regulatory review by the British Columbia Securities Commission (BCSC), amendments to the offering, and clarifications about the company's operations and use of funds. The document is a press release clarifying previous disclosures and does not contain financial statements, detailed financial data, or comprehensive report content. It is not an annual or interim report, earnings release, or investor presentation. It is also not a regulatory filing in the sense of officer certifications or compliance documents, but rather a public announcement clarifying prior disclosures related to a capital raising activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to the company's fundraising offering and related disclosure clarifications.
2026-04-20 English
News release - English.pdf
Capital/Financing Update Classification · 80% confidence The document is a company press release clarifying details of its “LIFE Offering” securities distribution following a securities commission review, discussing amendments to the Report of Exempt Distribution, cancellation and re‐issuance of securities with holds, and use of proceeds. It is not an AGM, earnings release, or annual report but clearly relates to financing and capital structure updates. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a clarifying news release issued by Noveris Health Sciences Inc. following a review by the British Columbia Securities Commission (BCSC) regarding the company's LIFE Offering document and related news releases. It clarifies statements about the company's operations, use of funds, and business objectives related to the LIFE Offering. The document does not contain financial statements or detailed financial data but rather provides corrections and clarifications about previous disclosures and the company's status. It is essentially a regulatory announcement addressing disclosure issues and compliance with securities regulations. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-04-20 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 87% confidence The document is a Canadian regulatory Form 45-106F1 “Report of Exempt Distribution,” detailing the distribution of securities under a prospectus exemption (including numbers of units, pricing, exemption relied on, purchaser jurisdictions, and compensation to underwriter). It is not a financial results announcement, AGM material, nor an annual/interim report, but a detailed report on a financing (capital raising) event. Therefore, it falls under “Capital/Financing Update” (CAP).
2026-03-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.